DISEASE INDICATIONS: Cystic Fibrosis
MANUFACTURER: Vertex Pharmaceuticals (Europe) Ltd
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
, Symdeko is indicated for the treatment of patients with CF who have specific genetic mutations that are responsive to these medications. This combination therapy addresses the underlying cause of CF by improving the function of the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) protein, which is often dysfunctional in CF patients.
